Latest News for: w-inds

Edit

Documentary explores food insecurity in Ind.

The Indiana Times 11 Apr 2025
Indiana doesn't have any mountain ranges but for many Hoosiers – nearly one million – the "benefits cliff" is too steep to afford proper food and nutrition ... .
Edit

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

PR Newswire 10 Apr 2025
BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S.
Edit

IND HEMP and National Hemp Association (NHA) Introduce Groundbreaking Nutritional Approach to Malaria Relief with ...

Nasdaq Globe Newswire 08 Apr 2025
Strategic Collaboration to Advance Use of Omega-Rich Hemp Seed Oil for Health Resilience in Africa. Strategic Collaboration to Advance Use of Omega-Rich Hemp Seed Oil for Health Resilience in Africa ... .
Edit

Bioavailability and Bioequivalence Studies Submitted in NDAs and INDs Webinar

Nasdaq Globe Newswire 07 Apr 2025
Dublin, April 07, 2025 (GLOBE NEWSWIRE) -- The "Bioavailability and Bioequivalence Studies submitted in NDAs and INDs" training has been added to ResearchAndMarkets.com's offering.
Edit

Starmab Biomed's First-In-Class, Dual-Target Anti-Tumor Drug SM2275 For Novel Immunotherapy Receives FDA IND Approval

MENA FN 07 Apr 2025
(MENAFN - EIN Presswire). StarMab announces that US FDA has approved its Investigational New Drug (IND) application for SM2275, a novel dual-target nanobody-based anti-tumor therapy. The IND ... .
Edit

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer (Form 6-K) (CureVac NV)

Public Technologies 07 Apr 2025
FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel ... FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer ... IND clearance ...
Edit

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based ...

ACCESSWIRE 07 Apr 2025
FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer ... IND clearance highlights CureVac's continued oncology pipeline growth, with more candidates planned to enter the clinic in 2026.
Edit

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Pharmiweb 07 Apr 2025
FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel ... FDA cleared IND application for CVHNLC, CureVac’s investigational therapy targeting squamous non-small cell lung cancer Proprietary ...
×